{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"TARGET","nct_id":"NCT05526755","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=target-nct05526755. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TARGET","arms":[{"description":"Participants will receive osimertinib (AZD9291).","label":"Osimertinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-11-22","type":"ESTIMATED"},"conditions":["Stage II-IIIB Non-small Cell Lung Carcinoma"],"enrollment":{"count":188,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib 80 mg/40 mg","otherNames":["AZD9291","TAGRISSO™"],"type":"DRUG"}],"last_update":"2026-08-03","lead_sponsor":"AstraZeneca","official_title":"An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants With EGFRm-positive Stage II-IIIB NSCLC, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-11-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Estimate the Efficacy of Osimertinib as Measured by Disease Free Survival (DFS) [Common EGFRm Cohort].","timeFrame":"From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 5 years."}],"references":[{"citation":"Soo RA, de Marinis F, Han JY, Ho JC, Martin E, Servidio L, Sandelin M, Popat S. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection. Clin Lung Cancer. 2024 Jan;25(1):80-84. doi: 10.1016/j.cllc.2023.09.005. Epub 2023 Oct 4.","pmid":"37914594","type":"DERIVED"}],"start_date":{"date":"2023-03-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","url":"https://clinicaltrials.gov/study/NCT05526755"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/target-nct05526755"}